2007
Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model
Wu AC, Paltiel AD, Kuntz KM, Weiss ST, Fuhlbrigge AL. Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model. Journal Of Allergy And Clinical Immunology 2007, 120: 1146-1152. PMID: 17904628, PMCID: PMC3476046, DOI: 10.1016/j.jaci.2007.07.055.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsCost-effectiveness ratioSevere asthmaEvent ratesSevere allergic asthmaQuality-adjusted monthsAllergic asthmaMost patientsAlternative medicationsHigher acquisition costUS FoodAsthmaDrug AdministrationLife yearsPatientsIncremental costDisease managementOmalizumabCost-effective optionTreatmentAcquisition costsEconomic outcomesCorticosteroidsMedicationsClinicians
2001
Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: Results from the Asthma Policy Model
Paltiel AD, Fuhlbrigge AL, Kitch BT, Liljas B, Weiss ST, Neumann PJ, Kuntz KM. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: Results from the Asthma Policy Model. Journal Of Allergy And Clinical Immunology 2001, 108: 39-in4. PMID: 11447380, DOI: 10.1067/mai.2001.116289.Peer-Reviewed Original ResearchConceptsSymptom-free daysCorticosteroid therapyAcute exacerbationModerate asthmaHealth-related qualityPopulation of patientsCost-effectiveness findingsHealth care costsCost-effectiveness analysisTotal health costsAdult asthmaObservational cohortRandomized trialsPatient preferencesPatient surveyClinical impactCorticosteroidsSide effectsCare costsDrug efficacyNatural historyAsthmaIncremental costTherapyMild